Lung Cancer Trial, Recruiting (NCT06849518)

Lung Cancer Trial, Recruiting NCT06849518 Sponsor: Ballad Health Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06849518 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with stage IV or inoperable stage IIIB non-small cell lung cancer (a specific type of lung cancer) who are not planning to have radiation therapy as their main treatment.
People who are receiving a type of immunotherapy drug that targets something called PD-1 or PD-L1, including those receiving it in combination with chemotherapy or with another type of immunotherapy drug targeting CTLA-4.
People who have given their documented consent to participate, after being fully informed that taking part is voluntary and that their care will not be affected by their decision either way.

Who may not be able to join:

People who are not receiving a PD-1 or PD-L1 targeting immunotherapy drug as part of their treatment.
People who have radiation therapy planned as their primary (main) treatment.
People whose lung cancer has been identified as small-cell lung cancer (a different type of lung cancer from the one this trial focuses on).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 7 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 423-431-5654

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06849518

Sponsor: Ballad Health

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: 423-431-5654

More information: https://clinicaltrials.gov/study/NCT06849518

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with stage IV or inoperable stage IIIB non-small cell lung cancer (a specific type of lung cancer) who are not planning to have radiation therapy as their main treatment.
People who are receiving a type of immunotherapy drug that targets something called PD-1 or PD-L1, including those receiving it in combination with chemotherapy or with another type of immunotherapy drug targeting CTLA-4.
People who have given their documented consent to participate, after being fully informed that taking part is voluntary and that their care will not be affected by their decision either way.

Who may not be able to join:

People who are not receiving a PD-1 or PD-L1 targeting immunotherapy drug as part of their treatment.
People who have radiation therapy planned as their primary (main) treatment.
People whose lung cancer has been identified as small-cell lung cancer (a different type of lung cancer from the one this trial focuses on).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 7 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ballad Health

Registry

ClinicalTrials.gov

Start date

11 February 2025

Est. completion

1 March 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Correlation of plasma cfRNA PD-L1 by qPCR expression* with ICI treatment and response.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov